A new oral contraceptive made from a combination of hormones similar to a woman's own has been approved by the Therapeutic Goods Administration.
ZOELY (nomegestrol acetate/oestradiol) is made of a highly-selective progestogen (nomegestrol acetate - NOMAC) derived from progesterone and an oestrogen (17β-oestradiol – E2) that is structurally identical to endogenous oestrogen produced naturally in a woman's body.
Through synergistic effects of NOMAC and E2, ZOELY delivers greater than contraceptive efficacy, short, light and less painful withdrawal bleeds compared to ethinyloestradiol and drospirenone, with a neutral effect on acne and weight for most patients. It is offered in a 24/4 monophasic regimen.
Dr Terri Foran, sexual health physician, said that the TGA approval of ZOELY further widened the pool of oral contraceptives that...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.